CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma

Abstract Background Chimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant therapeutic effect in hematologic malignancies, few successes have been obtained in solid tumors including esophageal squamous cell carcinoma (ESCC...

Full description

Bibliographic Details
Main Authors: Tingdang Liu, Ximing Dai, Yien Xu, Tian Guan, Liangli Hong, Tahir Zaib, Qi Zhou, Ke Cheng, Xiaoling Zhou, Changchun Ma, Pingnan Sun
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Journal of Translational Medicine
Subjects:
Esophageal squamous cell carcinomas
CD22
CAR-NK cell therapy
Immunotherapy
Solid tumor
Online Access:https://doi.org/10.1186/s12967-023-04409-8

Internet

https://doi.org/10.1186/s12967-023-04409-8

Similar Items